NYSE:PFE Pfizer (PFE) Stock Price, News & Analysis $29.05 +0.16 (+0.54%) As of 12:44 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Pfizer Stock (NYSE:PFE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pfizer alerts:Sign Up Key Stats Today's Range$28.91▼$29.2850-Day Range$27.42▼$30.7952-Week Range$23.62▼$31.44Volume9.76 million shsAverage Volume39.60 million shsMarket Capitalization$165.56 billionP/E Ratio41.49Dividend Yield5.92%Price Target$30.32Consensus RatingHold Company Overview Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech. Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, the company has grown into an international business serving patients and healthcare providers in markets around the world.AI Generated. May Contain Errors. Read More Pfizer Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScorePFE MarketRank™: 2.796655163255 of 5 starsPfizer scored higher than 56% of companies evaluated by MarketBeat, and ranked 453rd out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingHold Consensus RatingPfizer has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on no strong buy ratings, 6 buy ratings, 14 hold ratings, and 2 sell ratings.Upside/DownsideThe consensus price target for Pfizer is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoveragePfizer has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pfizer's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-2.63% Earnings GrowthEarnings for Pfizer are expected to decrease by -2.63% in the coming year, from $3.04 to $2.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pfizer is 41.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.32.Price to Earnings Ratio vs. SectorThe P/E ratio of Pfizer is 41.27, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.58.Price to Earnings Growth RatioPfizer has a PEG Ratio of 1.90. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioPfizer has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pfizer's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.37% of the float of Pfizer has been sold short.Short Interest Ratio / Days to CoverPfizer has a short interest ratio ("days to cover") of 4.58.Change versus previous monthShort interest in Pfizer has recently decreased by 2.46%, indicating that investor sentiment is improving. Dividend4.2 / 5Dividend StrengthStrong Dividend LeadershipPfizer is a leading dividend payer. It pays a dividend yield of 5.97%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthPfizer has been increasing its dividend for 16 years.Dividend CoverageThe dividend payout ratio of Pfizer is 245.71%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Pfizer will have a dividend payout ratio of 58.11% next year. This indicates that Pfizer will be able to sustain or increase its dividend.Read more about Pfizer's dividend. News and Social Media3.4 / 5News Sentiment0.45 News SentimentPfizer has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Pfizer this week, compared to 10 articles on an average week.Search Interest116 people have searched for PFE on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows74 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 252% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pfizer insiders have not sold or bought any company stock.Percentage Held by Insiders0.62% of the stock of Pfizer is held by insiders.Percentage Held by Institutions68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pfizer's insider trading history. Receive PFE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PFE Stock News HeadlinesNovo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?November 14 at 12:12 PM | fool.comPfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?November 14 at 9:32 AM | fool.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.November 16 at 1:00 AM | American Alternative (Ad)Wall Street Zen Upgrades Pfizer (NYSE:PFE) to "Buy"November 14 at 1:37 AM | americanbankingnews.comPfizer (PFE) Secures $1.5 Billion For Berobenatide DevelopmentNovember 13 at 10:17 PM | finance.yahoo.comMortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double DigitsPanama City, Guanacaste in Costa Rica and Lagos, Portugal top one investor's list for rental income and long-term growth, with Portuguese mortgages from 2.6%.November 2, 2026 | marketbeat.com3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (PFE)Lincoln National, AbbVie and Phillips 66 offer dividends that pay investors through midterm volatility, backed by rising rates, steady drug demand and oil risk.October 23, 2026 | marketbeat.comTech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs (PFE)Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.October 20, 2026 | marketbeat.comSee More Headlines PFE Stock Analysis - Frequently Asked Questions How have PFE shares performed this year? Pfizer's stock was trading at $24.90 at the beginning of 2026. Since then, PFE shares have increased by 16.0% and is now trading at $28.8870. How were Pfizer's earnings last quarter? Pfizer Inc. (NYSE:PFE) released its earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts' consensus estimates of $0.74 by $0.14. The firm's revenue for the quarter was down .4% compared to the same quarter last year. Read the conference call transcript. Does Pfizer have any subsidiaries? The following companies are subsidiaries of Pfizer: ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and others. Who are Pfizer's major shareholders? Top institutional investors of Pfizer include Sumitomo Mitsui Trust Group Inc. (0.24%), Pzena Investment Management LLC (0.11%), Russell Investments Group Ltd. (0.09%) and Pictet Asset Management Holding SA (0.08%). Insiders that own company stock include Ronald E Blaylock and Scott Gottlieb. View institutional ownership trends. How do I buy shares of Pfizer? Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pfizer own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include NVIDIA (NVDA), AT&T (T), Johnson & Johnson (JNJ), Verizon Communications (VZ), Intel (INTC), Tesla (TSLA) and AbbVie (ABBV). Company Calendar Record date for 9/1 Dividend7/24/2026Ex-Dividend for 9/1 Dividend7/24/2026Dividend Payable9/01/2026Last Earnings11/03/2026Record date for 12/7 Dividend11/06/2026Ex-Dividend for 12/7 Dividend11/06/2026Today11/16/2026Jefferies Global Healthcare Conference11/17/2026Dividend Payable12/07/2026Fiscal Year End12/31/2026Next Earnings (Estimated)2/02/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 PFE's financial health is in the Green zone, according to TradeSmith. PFE has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:PFE CIK78003 Webwww.pfizer.com Phone(212) 733-2323Fax302-655-5049Employees75,000Year Founded1849Price Target and Rating Average Price Target for Pfizer$30.32 High Price Target$40.00 Low Price Target$25.00 Potential Upside/Downside+4.4%Consensus RatingHold Rating Score (0-4)2.18 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio41.49 Forward P/E Ratio9.81 P/E Growth1.9Net Income$7.77 billion Net Margins6.34% Pretax Margin6.69% Return on Equity19.88% Return on Assets8.52% Debt Debt-to-Equity Ratio0.67 Current Ratio1.42 Quick Ratio1.10 Sales & Book Value Annual Sales$63.63 billion Price / Sales2.60 Cash Flow$4.42 per share Price / Cash Flow6.57 Book Value$15.26 per share Price / Book1.90Miscellaneous Outstanding Shares5,699,854,000Free Float5,664,515,000Market Cap$165.56 billion OptionableOptionable Beta0.31 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:PFE) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfizer Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfizer With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.